Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa as First-Line Treatment in Inoperable NSCLC
NCT00173875Phase 2Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by National Taiwan University Hospital. Primary endpoint: Overall Response Rate. Started Mar 2005; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00173875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00173875.